Alvina D Chu, MD
Rheumatology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 17
- 3 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
17 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Chu’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
17 of 17 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A89065 · Current
Licensed to practise in California · since 2004 · expires 2028-09-30 · State University of New York at Buffalo School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$4,028
Medicare paid this office $4,028 for 22 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
Who their Medicare patients are
22 Original Medicare patients in 2024. Average age 70 · Health risk score 1.86. Sicker patients than 9 in 10 peers; the typical rheumatology clinician is at 1.38.
Conditions among them: High blood pressure 75%.
The office billed $23,597, Medicare allowed $5,718 and paid $4,028; for 47 services of 3 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 22 | 47 | 70 | 1.86 | $23,597 | $4,028 |
| 2023 | 23 | 40 | 75 | 1.20 | $15,270 | $2,835 |
| 2022 | 17 | 41 | 73 | 1.53 | $19,722 | $2,882 |
| 2021 | 17 | 37 | 74 | 1.18 | $20,680 | $2,414 |
| 2020 | 11 | 29 | 72 | 1.78 | $9,405 | $1,289 |
| 2019 | 19 | 37 | 70 | 1.24 | $3,500 | $2,206 |
| 2018 | 17 | 33 | 73 | 1.93 | $2,781 | $1,662 |
| 2017 | 23 | 49 | 68 | 1.76 | $7,057 | $2,523 |
| 2016 | 23 | 59 | 68 | 1.38 | $11,067 | $3,117 |
| 2015 | 22 | 40 | 66 | 1.22 | $7,661 | $2,657 |
| 2014 | 22 | 52 | 64 | 1.08 | $9,634 | $3,429 |
| 2013 | 23 | 60 | 63 | 1.06 | $11,497 | $3,688 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 2 services
| Return visit (30+ min) | 16 | $1,737 | $83 |
| Short return visit (20+ min) | 15 | $1,098 | $58 |
2021: 1 service
| Short return visit (20+ min) | 12 | $1,068 | $49 |
2019: 1 service
| Return visit (30+ min) | 16 | $1,866 | $60 |
2018: 1 service
| Return visit (30+ min) | 16 | $1,439 | $60 |
2017: 1 service
| Return visit (30+ min) | 18 | $1,847 | $58 |
2016: 1 service
| Return visit (30+ min) | 17 | $2,383 | $58 |
2015: 1 service
| Return visit (30+ min) | 19 | $2,433 | $66 |
2014: 1 service
| Return visit (30+ min) | 21 | $3,342 | $67 |
2013: 1 service
| Return visit (30+ min) | 21 | $3,463 | $63 |
Drugs they prescribed that Part D paid
$72,377
Pharmacies billed $72,377 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 104) in 2024. At or below the middle of the specialty; the typical rheumatology clinician is at 3%.
94 generic and fewer than 11 brand-name prescriptions · $72,377 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Hydroxychloroquine Sulfate | 32 | $796 | $25 |
| Prednisone | 13 | $306 | $24 |
| Methotrexate | 13 | $198 | $15 |
Year by year
| 2024 | 104 | 18 | 0% (0) | None | $72,377 |
| 2023 | 98 | 14 | 0% (0) | 14% | $87,999 |
| 2022 | 105 | 11 | 0% (0) | 17% | $118,028 |
| 2021 | 128 | None | 0% (0) | 11% | $86,608 |
| 2020 | 114 | None | 0% (0) | 29% | $120,852 |
| 2019 | 151 | 14 | 0% (0) | 20% | $94,772 |
| 2018 | 165 | 18 | 0% (0) | 28% | $79,026 |
| 2017 | 183 | 16 | 0% (0) | 36% | $86,555 |
| 2016 | 132 | 11 | 0% (0) | 28% | $56,126 |
| 2015 | 136 | 12 | 0% (0) | 29% | $69,021 |
| 2014 | 218 | 15 | 0% (0) | 24% | $88,693 |
| 2013 | 241 | 18 | 0% (0) | 27% | $76,262 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 3 drugs
| Methotrexate | 17 | $1,047 | $62 |
| Hydroxychloroquine Sulfate | 17 | $888 | $52 |
| Prednisone | 14 | $103 | $7 |
2022: 3 drugs
| Hydroxychloroquine Sulfate | 20 | $1,177 | $59 |
| Methotrexate | 12 | $1,176 | $98 |
| Prednisone | 16 | $570 | $36 |
2021: 4 drugs
| Hydroxychloroquine Sulfate | 29 | $1,685 | $58 |
| Prednisone | 24 | $528 | $22 |
| Methotrexate | 18 | $337 | $19 |
| Ibuprofen | 12 | $126 | $11 |
2020: 3 drugs
| Hydroxychloroquine Sulfate | 19 | $2,009 | $106 |
| Prednisone | 27 | $354 | $13 |
| Ibuprofen | 11 | $181 | $16 |
2019: 4 drugs
| Hydroxychloroquine Sulfate | 19 | $1,749 | $92 |
| Methotrexate | 19 | $1,378 | $73 |
| Prednisone | 36 | $353 | $10 |
| Ibuprofen | 12 | $127 | $11 |
2018: 4 drugs
| Hydroxychloroquine Sulfate | 18 | $2,842 | $158 |
| Methotrexate | 30 | $2,803 | $93 |
| Prednisone | 39 | $534 | $14 |
| Ibuprofen | 14 | $140 | $10 |
2017: 5 drugs
| Hydroxychloroquine Sulfate | 24 | $4,240 | $177 |
| Leflunomide | 13 | $2,865 | $220 |
| Methotrexate | 36 | $2,014 | $56 |
| Prednisone | 43 | $460 | $11 |
| Ibuprofen | 12 | $23 | $2 |
2016: 5 drugs
| Leflunomide | 11 | $3,698 | $336 |
| Methotrexate | 29 | $1,085 | $37 |
| Hydroxychloroquine Sulfate | 14 | $1,049 | $75 |
| Prednisone | 31 | $472 | $15 |
| Ibuprofen | 11 | $18 | $2 |
2015: 6 drugs
| Humira | 11 | $35,298 | $3,209 |
| Hydroxychloroquine Sulfate | 17 | $2,246 | $132 |
| Leflunomide | 14 | $2,138 | $153 |
| Methotrexate | 13 | $1,703 | $131 |
| Prednisone | 30 | $489 | $16 |
| Ibuprofen | 11 | $127 | $12 |
2014: 9 drugs
| Humira | 11 | $29,322 | $2,666 |
| Xeljanz | 12 | $27,784 | $2,315 |
| Methotrexate | 17 | $1,976 | $116 |
| Pilocarpine | 16 | $1,256 | $78 |
| Leflunomide | 22 | $961 | $44 |
| Prednisone | 58 | $760 | $13 |
| Hydroxychloroquine Sulfate | 19 | $378 | $20 |
| Allopurinol | 11 | $152 | $14 |
| Ibuprofen | 11 | $122 | $11 |
2013: 8 drugs
| Humira | 12 | $27,916 | $2,326 |
| Enbrel | 11 | $25,124 | $2,284 |
| Methotrexate | 24 | $2,439 | $102 |
| Leflunomide | 19 | $907 | $48 |
| Prednisone | 60 | $597 | $10 |
| Hydroxychloroquine Sulfate | 17 | $270 | $16 |
| Omeprazole | 18 | $150 | $8 |
| Naproxen | 11 | $96 | $9 |
Money from drug and device companies
$65 in 2022
| 2022 | 2 | 2 | None | $65 |
| 2019 | 1 | 1 | None | $108 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Takeda Pharmaceuticals U.S.A. | Entyvio | $41 | 1 payment
|
| Pfizer | Cibinqo | $24 | 1 payment
|
See all 2 published payments
| Takeda Pharmaceuticals U.S.A. | Meals · 2022-05-22 | Entyvio | $41 |
| Pfizer | Meals · 2022-03-27 | Cibinqo | $24 |
See earlier years (2019)
2019: $108
| Ucb | Cimzia | $108 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1538355375
- Licence
- CA A89065California A89065: Current · expires 2028-09-30
- Trained
- State University of New York at Buffalo School of Medicine, 2002
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RR0500X (207RR0500X)
- Mailing address
- 900 Blake Wilbur Dr Rm W20812nd, Palo Alto, CA, 94304
- NPI first listed
- 2007-09-14
- NPI last updated
- 2024-04-28
- NPI record certified
- 2024-04-28
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 300 Pasteur Dr, Palo Alto, CA, 94304